WELCOME

The jury awarded $1 million to Purdue in the opioid

April 13, 2017 by Carolyn Mueller

The jury awarded $1 million to Purdue in the opioid case, with the company filing a $3.5 million civil penalty. In an interview last month, Purdue said the company will continue to fight for its rights under the law.

On the morning of January 18, 2017, Purdue announced that it will not sell the brand for more than ten months. Purdue's legal team accused the Justice Department of criminal negligence and is now pursuing civil fraud charges against the company for allegedly stealing $300 million from an estimated $30 million in the US Treasury.

Purdue's lawsuit claims that OxyContin "has a unique, addictive effect that is associated with addiction and has a long, unpredictable life cycle" and that OxyContin is a "dangerous poison from an opioid perspective."

The company says the DEA's findings "suggest[ed] that the current opioid crisis can be remedied with the use of effective treatment tools and increased availability of prescription opioids."

However, the Justice Department says that "the [Purdue] brand does not meet any of the specific criteria outlined by the DEA and DEA Administrator" of the US Drug Enforcement Administration for prescription opioid use, and that "the product and products containing it are not available as a regulated substance."

Purdue contends it has been unfairly targeted by the DEA for selling OxyContin to its customers.

The company also has been accused of selling OxyContin in "false" and "unduly deceptive" terms.

In its first day selling the product, the company said the DEA's report "found that the product did not meet its stated safety, effectiveness, or potential for abuse as a pain reliever."

When asked if it has taken any steps to remedy the pain, the company said "We never took any action to remove the product from its packaging, nor were we forced to. We are committed to fighting and improving the safety of our products and continuing to fight for our rights to use this brand. We will be taking additional steps to ensure the safety of our products and products through our retail distribution efforts in the United States."

According to Purdue's lawsuit, Purdue was the primary supplier to OxyContin. It is alleged that it had "diluted" OxyContin and then sold it and other opioids to its customers, in violation of federal law and the Controlled Substances Act.

In the US, OxyContin is legal in only two states that provide "diluting" opioids to consumers. In North Carolina, consumers are subject to a $15 daily charge for OxyContin under the